Side-by-side · Research reference
KPVvsPinealon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft13/39 cited
BHuman-MechanisticDraft12/36 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
01Mechanism of Action
Parameter
KPV
Pinealon
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Feedback intact?
No melanocortin receptor binding
—
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
Pinealon
Frequency
Daily or 2–3× per week
Once daily during cycle
Lower / starter dose
100 mcg / day
2.5 mg / day
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Russian clinical trials + in vitroKhavinson 2014
Duration
4–8 weeks per cycle
10-day cycles, 1–2× per year
Reconstitution
Bacteriostatic water (SQ form)
Bacteriostatic water
Timing
No specific time; often taken with / before meals (oral)
No specific time
Half-life
Hours (estimated; rapid tissue uptake)
Hours
04Side Effects & Safety
Parameter
KPV
Pinealon
Injection site reaction
Mild irritation
Mild irritation
GI symptoms
Rare nausea (oral form)
—
Long-term safety
Limited human data
Limited Western data
Pregnancy / OB
Avoid — insufficient data
Avoid
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
Pinealon
- ·Pregnancy / breastfeeding
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
05Administration Protocol
Parameter
KPV
Pinealon
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Add 1–2 mL bacteriostatic water to 10 mg vial.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
SQ — abdomen preferred.
3. Timing
Morning preferred; oral form taken with / before meals.
Daily during cycle, any time.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G insulin syringe (SQ form).
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation